Abstracts tagged "Damage Index"

Abstract Number: 2422 • ACR Convergence 2025
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
Oihane Ibarguengoitia-Barrena¹, Leyre Riancho Zarrabeitia², Iñigo Rúa-Figueroa³, Karen Roberts⁴, Victor Martinez-Taboada⁵, Raúl Menor Almagro⁶, Belén Serrano-Benavente⁷, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernández-Nebro¹⁰, Maria Esther Ruiz Lucea¹¹, Jaime Calvo¹², Jose Francisco Garcia Llorente¹³, EVA GLORIA TOMERO MURIEL¹⁴, Maria Esther Uriarte¹⁵, Mercedes Freire González¹⁶, Angela Pecondón-Español¹⁷, Javier García-Fernández¹⁸, Lorena Expósito-Pérez¹⁹, Monica Ibañez Barcelo²⁰, Elena Aurrecoechea²¹, Carlos Montilla²², Jose Rosas Gómez de Salazar²³, Maria Garcia-Villanueva²⁴, Rocío Caño²⁵, Francisco Javier Toyos²⁶, Francisco Javier Novoa²⁷, Clara Moriano²⁸, Gema Bonilla²⁹, Javier Narváez³⁰, Jose Luis Andreu³¹, Marta Arévalo-Salaet³², Loreto Horacda-Rubio³³, Tatiana Cobo-Ibáñez³⁴, Nuria Lozano Rivas³⁵, Cristina Bohorquez³⁶, Carlota Laura Iniguez Ubiaga³⁷, Eva salgado-Pérez³⁸, Vicente Torrente Segarra³⁹, CARLOS TAREK SALMAN MONTE⁴⁰, JOSE ELOY OLLER RODRIGUEZ⁴¹ and José María Pego-Reigosa⁴², ¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²Hospital Sierrallana, Santander, Spain, ³Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁴Buenos Aires Instituto, West Reading, CA, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Universitario Donostia, San Sebastian, Spain, ¹⁶⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁹University Clinical Hospital of Canarias, Tenerife, Spain, ²⁰Son Llàtzer University Hospital, Palma de Mallorca, Spain, ²¹Hospital Sierrallana, CANTABRIA, Spain, ²²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Hospital Ramón y Cajal, Madrid, Spain, ²⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁶Virgen Macarena University Hospital,, Sevilla, Spain, ²⁷Hospital Insular de Gran Canaria, Las palmas, ²⁸Hospital León, LEON, Castilla y Leon, Spain, ²⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³²Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Infanta Sofia Hospital, Madrid, Spain, ³⁵Hospital Clínico Universitario Virgen de la Arrixaca,, Murcia, Spain, ³⁶La Paz University Hospital, Alcalá De Henares, Spain, ³⁷SERV. REUMATOLOGIA, Lugo, Spain, ³⁸Complejo Hospitalario de Orense, Santiago de Composte, Spain, ³⁹Hospital Comarcal del Alt Penedes, Madrid, Spain, ⁴⁰Hospital del Mar, Barcelona, Spain, ⁴¹HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁴²Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where…
Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 2416 • ACR Convergence 2025
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Megan Barber¹, John Hanly², Murray Urowitz³, Ian Bruce⁴, Yvan St-Pierre⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Francisco Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David A. Isenberg¹², Anisur Rahman¹², Joan Merrill¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Michelle Petri¹⁶, Ellen Ginzler¹⁷, Mary Anne Dooley¹⁸, Rosalind Ramsey-Goldman¹⁹, Susan Manzi²⁰, Andreas Jönsen²¹, Graciela Alarcón²², Ronald van Vollenhoven²³, Cynthia Aranow²⁴, Meghan mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanç²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken⁸, Diane Kamen³¹, Anca Askanase³² and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, South Korea, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷SUNY Downstate Health Sciences University, New York, NY, ¹⁸UNC physician network, Chapel Hill, NC, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²¹Department of Clinical Sciences, Lund University, Lund, Sweden, ²²The University of Alabama at Birmingham, Oakland, CA, ²³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁴Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Biobizkaia Health Research Institute, Barakaldo, Spain, ²⁷Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹Medical University of South Carolina, Johns Island, SC, ³²Columbia University Medical Center, New York, NY
Background/Purpose: We reported partial direct healthcare costs associated with damage accrual in the SLICC Inception Cohort (Barber M. Arthritis Care Res 2020;72:1800). We have supplemented…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 2387 • ACR Convergence 2025
Lupus Damage Index Revision – Item Generation and Reduction Phases
Burak Kundakci¹, Megan Barber², Ann Clarke², Sindhu Johnson³ and Ian Bruce⁴, ¹Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom
Background/Purpose: The current Systemic Lupus Erythematosus Damage Index (SDI) is a robust instrument, but is limited by missing items, restricted applicability in pediatric patients, and…
Abstract Number: 2071 • ACR Convergence 2025
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
valeria cantu¹, Rebeca L. Polina-Lugo¹, Emmanuel Dominguez-Chapa², Ana Cecilia Bardan Inchaustegui³, Fernanda M. Garcia-Carrillo⁴, Daniela A. Mejia-Rodriguez⁴, Ericka S. Reyna-Hernandez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Miguel Villarreal-Alarcón⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Hospital Universitario UANL, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…
Abstract Number: 2058 • ACR Convergence 2025
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
valeria cantu¹, Emmanuel Dominguez-Chapa², Rebeca L. Polina-Lugo¹, Ana Cecilia Bardan Inchaustegui³, fernanda m. garcia-Carrillo⁴, Ericka S. Reyna-Hernandez⁵, Daniela A. Mejia-Rodriguez⁵, Rosa Arvizu-Rivera⁶, Jesus Alberto Cardenas-de la Garza⁷, Miguel Villarreal-Alarcón⁸ and Dionicio A. Galarza-Delgado⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
Abstract Number: 2053 • ACR Convergence 2025
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Agustin Hernández-López¹, Nancy R Mejía Domínguez², Yatzil Reyna Juárez³, María José Ostos Prado⁴, Beatriz Alcalá Carmona⁵, Jennifer Tiaré Balderas Miranda⁶, Carlos A. Núñez-Álvarez⁵, Marta E. Baños-Laredo⁷, Diana Gómez-Martín⁸ and Jiram Torres-Ruiz⁹, ¹Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, ²Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁶Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁷INCMNSZ, Cdmx, Mexico, ⁸INCMNSZ, Mexico city, Federal District, Mexico, ⁹INCMNSZ, Ciudad de México, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscular inflammation that can affect any organ or system. Reported mortality rates…
Abstract Number: 1899 • ACR Convergence 2025
Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Manuel Ugarte-Gil¹, Sarah Gasman², Federico Zazzetti³, Ashley Orillion², Anna Sheahan⁴, Clair Blacketer², Michel van Speybroeck⁵, Reyhan Sonmez⁶, Erika Noss², Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, Maria Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ²Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁵Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁶Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: SLE is characterized by heterogeneous clinical presentation and periods of flare and remission, with variation in management globally. A goal for SLE management is…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1469 • ACR Convergence 2025
Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
Adriana Vázquez-Hernández¹, Emilio Godinez-Lazarini², Erik Cimé-Aké² and Hilda Fragoso-Loyo³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: In systemic lupus erythematosus (SLE), differences have been observed between patients of different ages at onset. This study evaluates remission, low disease activity, and…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1154 • ACR Convergence 2025
Assessment Of Damage Using The IgG4-Related Disease Damage Index.
Eduardo Martin-Nares¹ and Gabriela Hernandez-Molina², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder affecting multiple organs, often leading to irreversible damage. Standardized tools like the IgG4-RD Damage Index (DI)…
Abstract Number: 0636 • ACR Convergence 2025
AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways
Sepehr Taghavi¹, Ines Silva², Jacob Vasquez³, Vasileios Kyttaris⁴, Tyler O'Malley⁵ and Mike Nerenberg⁶, ¹Exagen Inc, Escondido, CA, ²Exagen, Carlsbad, CA, ³Exagen, Inc., Vista, CA, ⁴Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵Exagen, Vista, CA, ⁶Exagen, DEL MAR, CA
Background/Purpose: Lupus nephritis (LN) and diabetic kidney disease (DKD) are leading causes of chronic kidney disease (CKD) that differ by age, sex, and underlying mechanisms.…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].